United Therapeutics Remodulin
Executive Summary
FDA's Cardiovascular & Renal Drugs Advisory Committee will review the Remodulin NDA (21-272) for treatment of pulmonary hypertension during the morning of Aug. 9. The firm anticipates action on the application shortly following the meeting (1"The Pink Sheet" July 2, p. 18)